Bide Pharmatech

What Bide Pharmatech does

Bide Pharmatech (Shanghai Bide Pharmaceutical Technology Co., Ltd. / 上海毕得医药科技股份有限公司) is a Shanghai-headquartered, privately held chemical supplier founded in 2007 that manufactures and distributes molecular building blocks, pharmaceutical intermediates, catalysts and ligands, life-science reagents, and materials-science chemicals. The company operates one of the largest in-stock catalogs of heterocyclic, fluorinated, and bridged-ring (BCP, BCO, BCHep) compounds in China, with more than 100,000 products available for immediate shipment, and supports customers with full per-batch QC documentation (COA, NMR, HPLC, GC). A 5,000+ sqm R&D center in Shanghai's Songjiang district staffed by 300+ chemists delivers end-to-end custom synthesis from laboratory development through process scale-up and GMP production; the company reports over 10,000 completed custom synthesis projects and five registered Chinese invention patents covering synthesis methods.

Bide monetizes through two streams: one-time catalog sales of research chemicals and building blocks priced on a unit basis with purity grades from 90%+ to 99%+ in packaging from mg to kg scale, and project-based custom synthesis and process development services. Pricing is not publicly disclosed; transactions are routed through a proprietary e-commerce storefront (bidepharm.com) backed by a direct regional sales force covering nearly every Chinese province. Discovery is enabled by an in-house structure-search engine supporting chemical drawing, batch search, fuzzy chemical-name matching, and MDL/MOL format imports. Distribution rests on five warehouses — Shanghai, Shenzhen, Tianjin, Wuhan, and Chengdu — and dedicated sales hotlines segmented by region and by buyer type (enterprise vs. academic).

Bide serves pharmaceutical and biotech companies, academic and research institutions, and a growing base of materials-science researchers (MOF/COF, OLED, battery materials). Government designations include National High-Tech Enterprise and National Specialized, Refined, and New "Small Giant" Enterprise (both 2021), and collaborative research relationships span the Shanghai Institute of Organic Chemistry, Fudan University, Shanghai Jiao Tong University, Guangzhou Medical University, and USTC. In January 2025, Bide (with partner funds) acquired US-based Combi-Blocks for USD 215 million, marking its first significant overseas footprint.

Name

Bide Pharmatech

Legal name

Shanghai Bide Pharmaceutical Technology Co., Ltd. (上海毕得医药科技股份有限公司)

Website

https://bidepharm.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Bide Pharmatech is a Shanghai-based supplier of pharmaceutical intermediates, molecular building blocks, catalysts, ligands, and life-science reagents, serving pharmaceutical, biotech, academic, and materials-science customers through a 100,000+ SKU catalog and custom synthesis services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Intermediates & Research Chemicals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical intermediates
• Molecular building blocks
• Heterocyclic compounds
• Custom synthesis services
• Research chemicals

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Chemicals and Building Blocks Sales: Sale of pharmaceutical intermediates, heterocyclic building blocks, organic building blocks, catalysts, ligands, and life science compounds to pharmaceutical companies, biotech firms, and research institutions.
2. Custom Synthesis Services: R&D custom synthesis services including laboratory development, process scale-up, and GMP factory production for drug molecule synthesis projects.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Bide Pharmatech manufactures and supplies a catalog of over 100,000 pharmaceutical intermediates, molecular building blocks (heterocyclic, fluorinated, boronic acid, bridged/spiro rings), catalysts and ligands, life science reagents, and materials science compounds. The company also provides custom synthesis services from laboratory development through process scale-up to GMP production, backed by a 5,000+ sqm R&D center in Shanghai. Products are sold through the company's own e-commerce platform and direct sales channels to pharmaceutical companies, biotech firms, and academic research institutions.

Product overview

Bide Pharmatech (毕得医药) operates as a comprehensive research chemical e-commerce platform offering over 100,000 in-stock products across molecular building blocks, catalysts and ligands, life sciences, materials science, and synthetic reagents. The company also provides custom synthesis services through its 5,000+ sqm Shanghai R&D center with 300+ researchers. Key product lines include fluorinated building blocks, heterocyclic building blocks, boron and boronic esters, and MOF ligands. The platform enables researchers to search, browse, and purchase pharmaceutical intermediates and research chemicals through its online catalog with real-time inventory tracking, quality documentation downloads (COA, NMR, HPLC), and batch traceability.

Differentiator

Problem solved

Functional benefit

Products and services

• Molecular Building Blocks (分子砌块) Comprehensive catalog of molecular building blocks including boronic acids/esters, aromatic rings, aromatic heterocycles, fluorinated building blocks, spirocycles, bridged rings (BCP, BCO, BCHep), aliphatic rings, aliphatic heterocycles, stable free radical blocks, and partially saturated cycles for pharmaceutical research and drug development.
• Catalysts and Ligands (催化剂配体) Extensive range of catalysts and ligands for organic synthesis including transition metals, lanthanides, metalloids, main group metals, chiral phosphine ligands (BIDIME, BIBOP, Sadphos), chiral oxazoline ligands, chiral nitrogen ligands, chiral oxygen ligands, N-heterocyclic carbenes (NHCs), achiral phosphine ligands, photoredox catalysts, chiral organocatalysts, and phase transfer catalysts.
• Life Sciences Products (生命科学) Life science research products including molecular biology reagents, inhibitors and agonists, PROTAC molecules, antibody-drug conjugates (ADC payloads), and biochemical reagents for drug discovery research.
• Materials Science Products (材料科学) Materials for advanced research including electronic materials, covalent organic frameworks (COF), metal-organic frameworks (MOF), solar cell materials, battery materials, OLED materials, and polymer additives.
• Synthetic Reagents (合成试剂) Synthetic reagents including organometallic reagents, halogenation reagents, reduction agents, oxidation agents, and chiral resolving agents for organic synthesis applications.
• Custom Synthesis Services (定制合成) Bespoke chemistry services with 5,000+ sqm Shanghai R&D center and 300+ experienced researchers, supporting laboratory development, process scale-up, and GMP production for drug molecule synthesis projects. The company has completed 10,000+ custom synthesis projects with multiple national invention patents.
• Fluorinated Building Blocks (含氟砌块) Specialized fluorinated building blocks including trifluoromethyl, difluoromethyl, trifluoromethoxy, aromatic fluorides, sulfonyl fluorides, SF5-containing, and aliphatic fluorinated compounds for pharmaceutical applications.
• Heterocyclic Building Blocks (杂环砌块) Heterocyclic compounds including pyridines, pyrroles, thiazoles, quinolines, pyrimidines, triazines, tetrazoles, oxazoles, imidazoles, and fused ring systems used as pharmaceutical intermediates.
• Boron and Boronic Esters (硼酸及硼酸酯) Boronic acids and esters including fluorinated, halogenated, aromatic, and heterocyclic derivatives for Suzuki coupling reactions and other cross-coupling applications.
• Metal-Organic Framework (MOF) Ligands MOF ligand building blocks including carboxylic acid MOF ligands, nitrogen-containing MOF ligands, and carboxylate-nitrogen MOF ligands for advanced materials synthesis.
• DEL-Compatible Scaffolds Library DNA-encoded library (DEL) compatible scaffold compounds for drug discovery research.
• Skeleton Compound Library (骨架化合物库) Compound library based on skeleton hopping methods for structure optimization research in new drug development.
• Lead Compound Library (先导化合物库) Lead compound library for drug discovery screening applications.

Quantifiable outcome

• 100,000+ products in stock with ready availability
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Combi-BlockscoreStrategic or Co-development Partner · 14 January 2025Bide and partner funds acquired US lab reagent maker Combi-Blocks for USD 215 million in January 2025. This acquisition expands Bide's presence in the US market and strengthens its capabilities in laboratory reagent manufacturing for pharmaceutical research.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Chem-Impex International: US-based supplier of research chemicals, intermediates, and building blocks; comparable in catalog breadth, customer mix, and custom synthesis capabilities, especially for the North American market.
• PharmaBlock Sciences: Chinese-headquartered catalog and CDMO peer specializing in building blocks, reference compounds, and custom synthesis; closest direct competitor with overlapping product categories and customer base in pharma/biotech.
• Enamine: Ukraine-headquartered supplier of building blocks and screening compounds, notably the REAL database and custom synthesis; comparable in catalog scale and pharma/biotech customer focus.
• J&K Scientific: Chinese-headquartered supplier of laboratory reagents, chemicals, and building blocks with broad catalog and custom synthesis; overlaps significantly with Bide across product lines and customer segments.
• TCI Chemicals: Japanese-headquartered specialty chemicals supplier with a deep catalog of organic building blocks, catalysts, and reagents; comparable to Bide in product mix and academic/customer base, though stronger in Western markets.
• Combi-Blocks: US-based supplier of chemical building blocks and screening compounds; acquired by Bide in January 2025 for $215M and now operated as a wholly-owned subsidiary, but functions as a direct peer in the building-blocks e-commerce space alongside its parent.
• Shanghai Haoyuan Chemexpress: Shanghai-based peer offering building blocks, screening libraries, and custom synthesis to pharma and biotech; directly overlaps with Bide in Chinese and global customer segments.

Emerging players

• Fluorochem: UK-based specialty supplier with strong position in fluorinated building blocks and heterocycles; a partial overlap with Bide that is particularly relevant given Bide's fluorination specialization.

Broad incumbents

• Alfa Aesar (Thermo Fisher Scientific): Research chemicals and building blocks brand owned by Thermo Fisher; competes across Bide's catalog with the backing of Thermo Fisher's global logistics and enterprise sales force.
• Sigma-Aldrich (Merck KGaA): The largest global research chemicals and building blocks supplier under Merck's Life Science division; competes across Bide's full catalog with much broader portfolio depth and entrenched enterprise relationships.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bide Pharmatech